The DOI matches its Crossref record; 295 of the 299 references it cites were found in a registry or an index.
Interpretation of the evidence for the efficacy and safety of statin therapy
Open accessAbstract
This Review is intended to help clinicians, patients, and the public make informed decisions about statin therapy for the prevention of heart attacks and strokes. It explains how the evidence that is available from randomised controlled trials yields reliable information about both the efficacy and safety of statin therapy. In addition, it discusses how claims that statins commonly cause adverse effects reflect a failure to recognise the limitations of other sources of evidence about the effects of treatment. Large-scale evidence from randomised trials shows that statin therapy reduces the risk of major vascular events (ie, coronary deaths or myocardial infarctions, strokes, and coronary revascularisation procedures) by about one-quarter for each mmol/L reduction in LDL cholesterol during each year (after the first) that it continues to be taken. The absolute benefits of statin therapy depend on an individual's absolute risk of occlusive vascular events and the absolute reduction in LDL cholesterol that is achieved. For example, lowering LDL cholesterol by 2 mmol/L (77 mg/dL) with an effective low-cost statin regimen (eg, atorvastatin 40 mg daily, costing about £2 per month) for 5 years in 10 000 patients would typically prevent major vascular events from occurring in about 1000 patients (ie, 10% absolute benefit) with pre-existing occlusive vascular disease (secondary prevention) and in 500 patients (ie, 5% absolute benefit) who are at increased risk but have not yet had a vascular event (primary prevention). Statin therapy has been shown to reduce vascular disease risk during each year it continues to be taken, so larger absolute benefits would accrue with more prolonged therapy, and these benefits persist long term. The only serious adverse events that have been shown to be caused by long-term statin therapy-ie, adverse effects of the statin-are myopathy (defined as muscle pain or weakness combined with large increases in blood concentrations of creatine kinase), new-onset diabetes mellitus, and, probably, haemorrhagic stroke. Typically, treatment of 10 000 patients for 5 years with an effective regimen (eg, atorvastatin 40 mg daily) would cause about 5 cases of myopathy (one of which might progress, if the statin therapy is not stopped, to the more severe condition of rhabdomyolysis), 50-100 new cases of diabetes, and 5-10 haemorrhagic strokes. However, any adverse impact of these side-effects on major vascular events has already been taken into account in the estimates of the absolute benefits. Statin therapy may cause symptomatic adverse events (eg, muscle pain or weakness) in up to about 50-100 patients (ie, 0·5-1·0% absolute harm) per 10 000 treated for 5 years. However, placebo-controlled randomised trials have shown definitively that almost all of the symptomatic adverse events that are attributed to statin therapy in routine practice are not actually caused by it (ie, they represent misattribution). The large-scale evidence available from randomised trials also indicates that it is unlikely that large absolute excesses in other serious adverse events still await discovery. Consequently, any further findings that emerge about the effects of statin therapy would not be expected to alter materially the balance of benefits and harms. It is, therefore, of concern that exaggerated claims about side-effect rates with statin therapy may be responsible for its under-use among individuals at increased risk of cardiovascular events. For, whereas the rare cases of myopathy and any muscle-related symptoms that are attributed to statin therapy generally resolve rapidly when treatment is stopped, the heart attacks or strokes that may occur if statin therapy is stopped unnecessarily can be devastating.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Although LDL-lowering drugs have only moderate effects on TG levels, they reduce ASCVD risk in patients with and without HTG.42”
From Clinical review on triglycerides (2020) · cites this paper as [42]
Experimental — accuracy not yet measuredIn the citing paper
“Although LDL-lowering drugs have only moderate effects on TG levels, they reduce ASCVD risk in patients with and without HTG.42”
From Clinical review on triglycerides (2020) · cites this paper as [42]
In the citing paper
“Overall, statin therapy produced a 21% relative reduction in major vascular events (relative risk 0.79, 95% CI 0.77-0.81) per 1.0 mmoL/L reduction in LDL-C”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [217]
In the citing paper
“However, since the absolute risk of CAD is higher in older persons, the associated absolute increase in risk for a given increment in TC is larger with increasing age [217].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [217]
In the citing paper
“The relative reduction in major vascular events was similar, irrespective of age, among patients with pre-existing vascular disease, but appeared smaller among older individuals not known to have vascular disease.”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [217]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Reduced dietary salt for the prevention of cardiovascular disease
Taylor, R. S., Ashton, K. E., Moxham, T., Hooper, L., & Ebrahim, S. B. J. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009217.pub2 · Cited by 311
RetractedWriting Group for the Women's Health Initiative Investigators (2002) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.288.3.321 · Cited by 15,889
Sacks, F. M., Pfeffer, M. A., Moye, L. A., Rouleau, J. L., Rutherford, J. D., Cole, T. G., Brown, L., Warnica, J. W., Arnold, J. M. O., Wun, C.-C., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610033351401 · Cited by 7,439
Stone, N. J., Robinson, J. G., Lichtenstein, A. H., Bairey Merz, C. N., Blum, C. B., Eckel, R. H., Goldberg, A. C., Gordon, D., Levy, D., Lloyd-Jones, D. M., et al. (2014) · Circulation · doi:10.1161/01.cir.0000437738.63853.7a · Cited by 7,081
(2005) · The Lancet · doi:10.1016/s0140-6736(05)67394-1 · Cited by 6,848
Self-citationRosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein
Ridker, P. M., Danielson, E., Fonseca, F. A. H., Genest, J., Gotto, A. M., Kastelein, J. J. P., Koenig, W., Libby, P., Lorenzatti, A. J., MacFadyen, J. G., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0807646 · Cited by 6,674
Self-citationCholesterol Treatment Trialists' (CTT) Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)61350-5 · Cited by 6,550
Hulley, S. (1998) · JAMA · doi:10.1001/jama.280.7.605 · Cited by 6,216
The Emerging Risk Factors Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)60484-9 · Cited by 5,125
Research works printed but not linked: 3
- Abramson, 2013, Don't Give More Patients Statins, The New York Times
- 2013, Statins can weaken muscles and joints: cholesterol drug raises risk of problems by up to 20 per cent, MailOnline
- 2016, How Big Pharma greed is killing tens of thousands around the world: Patients are over-medicated and often given profitable drugs with ‘little proven benefits,’ leading doctors warn, MailOnline
Cited by
Sorted by citations
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz455 · Cited by 8,961
Self-citationKDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease
Stevens, P. E., Ahmed, S. B., Carrero, J. J., Foster, B., Francis, A., Hall, R. K., Herrington, W. G., Hill, G., Inker, L. A., Kazancıoğlu, R., et al. (2024) · Kidney International · doi:10.1016/j.kint.2023.10.018 · Cited by 8,530
2021 ESC Guidelines on cardiovascular disease prevention in clinical practice
Visseren, F. L. J., Mach, F., Smulders, Y. M., Carballo, D., Koskinas, K. C., Bäck, M., Benetos, A., Biffi, A., Boavida, J.-M., Capodanno, D., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab484 · Cited by 6,485
Grundy, S. M., Stone, N. J., Bailey, A. L., Beam, C., Birtcher, K. K., Blumenthal, R. S., Braun, L. T., de Ferranti, S., Faiella-Tommasino, J., Forman, D. E., et al. (2019) · Circulation · doi:10.1161/cir.0000000000000625 · Cited by 6,185
Self-citationEvolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
Sabatine, M. S., Giugliano, R. P., Keech, A. C., Honarpour, N., Wiviott, S. D., Murphy, S. A., Kuder, J. F., Wang, H., Liu, T., Wasserman, S. M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1615664 · Cited by 6,138
Self-citationMach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2019) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2019.08.014 · Cited by 4,854
Self-citationFerence, B. A., Ginsberg, H. N., Graham, I., Ray, K. K., Packard, C. J., Bruckert, E., Hegele, R. A., Krauss, R. M., Raal, F. J., Schunkert, H., et al. (2017) · European Heart Journal · doi:10.1093/eurheartj/ehx144 · Cited by 3,962
Mancia, G., Kreutz, R., Brunström, M., Burnier, M., Grassi, G., Januszewicz, A., Muiesan, M. L., Tsioufis, K., Agabiti-Rosei, E., Algharably, E. A. E., et al. (2023) · Journal of Hypertension · doi:10.1097/hjh.0000000000003480 · Cited by 3,473
Libby, P., Buring, J. E., Badimon, L., Hansson, G. K., Deanfield, J., Bittencourt, M. S., Tokgözoğlu, L., & Lewis, E. F. (2019) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0106-z · Cited by 3,211
The changing landscape of atherosclerosis
Libby, P. (2021) · Nature · doi:10.1038/s41586-021-03392-8 · Cited by 2,873
Grundy, S. M., Stone, N. J., Bailey, A. L., Beam, C., Birtcher, K. K., Blumenthal, R. S., Braun, L. T., de Ferranti, S., Faiella-Tommasino, J., Forman, D. E., et al. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.11.003 · Cited by 2,691
Self-citationGrundy, S. M., Stone, N. J., Bailey, A. L., Beam, C., Birtcher, K. K., Blumenthal, R. S., Braun, L. T., de Ferranti, S., Faiella-Tommasino, J., Forman, D. E., et al. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.11.002 · Cited by 1,751
Self-citation2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization
Lawton, J. S., Tamis‐Holland, J. E., Bangalore, S., Bates, E., Beckie, T. M., Bischoff, J. M., Bittl, J. A., Cohen, M. G., DiMaio, J. M., Don, C. W., et al. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.09.006 · Cited by 1,691
Biomarker definitions and their applications
Califf, R. M. (2018) · Experimental Biology and Medicine · doi:10.1177/1535370217750088 · Cited by 1,694
Facing up to the global challenges of ageing
Partridge, L., Deelen, J., & Slagboom, P. E. (2018) · Nature · doi:10.1038/s41586-018-0457-8 · Cited by 1,475
Lawton, J. S., Tamis‐Holland, J. E., Bangalore, S., Bates, E. R., Beckie, T. M., Bischoff, J. M., Bittl, J. A., Cohen, M. G., DiMaio, J. M., Don, C. W., et al. (2021) · Circulation · doi:10.1161/cir.0000000000001038 · Cited by 1,349
Hankey, G. J. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30962-x · Cited by 1,311
Effects of stress on the development and progression of cardiovascular disease
Kivimäki, M., & Steptoe, A. (2018) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2017.189 · Cited by 1,197
Reducing the Global Burden of Cardiovascular Disease, Part 1
Joseph, P. G., Leong, D. P., McKee, M., Anand, S. S., Schwalm, J.-D., Teo, K. K., Mente, A., & Yusuf, S. (2017) · Circulation Research · doi:10.1161/circresaha.117.308903 · Cited by 1,135
Self-citationEffects of anacetrapib in patients with atherosclerotic vascular disease
The HPS3/TIMI55–REVEAL Collaborative Group (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1706444 · Cited by 1,047
Grundy, S. M., Stone, N. J., Bailey, A. L., Beam, C. T., Birtcher, K. K., Blumenthal, R. S., Braun, L. T., de Ferranti, S. D., Faiella-Tommasino, J., Forman, D. E., et al. (2019) · Circulation · doi:10.1161/cir.0000000000000624 · Cited by 933
Self-citationRichardson, T. G., Sanderson, E., Palmer, T. M., Ala-Korpela, M., Ference, B. A., Davey Smith, G., & Holmes, M. V. (2020) · PLOS Medicine · doi:10.1371/journal.pmed.1003062 · Cited by 843
Self-citationArmitage, J., Baigent, C., Barnes, E., Betteridge, D. J., Blackwell, L., Blazing, M., Bowman, L., Braunwald, E., Byington, R., Cannon, C., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(18)31942-1 · Cited by 801
Self-citationBonaca, M. P., Nault, P., Giugliano, R. P., Keech, A. C., Pineda, A. L., Kanevsky, E., Kuder, J., Murphy, S. A., Jukema, J. W., Lewis, B. S., et al. (2018) · Circulation · doi:10.1161/circulationaha.117.032235 · Cited by 766
Self-citationWard, N. C., Watts, G. F., & Eckel, R. H. (2019) · Circulation Research · doi:10.1161/circresaha.118.312782 · Cited by 799
Newman, C. B., Preiss, D., Tobert, J. A., Jacobson, T. A., Page, R. L., II, Goldstein, L. B., Chin, C. C., Tannock, L. R., Miller, M. J., Raghuveer, G., et al. (2019) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atv.0000000000000073 · Cited by 790
Self-citationIntracerebral haemorrhage: current approaches to acute management
Cordonnier, C., Demchuk, A. M., Ziai, W., & Anderson, C. S. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31878-6 · Cited by 745
Atherosclerosis and inflammation: overview and updates
Geovanini, G. R., & Libby, P. (2018) · Clinical Science · doi:10.1042/cs20180306 · Cited by 711
Mendelian randomization in cardiometabolic disease: challenges in evaluating causality
Holmes, M. V., Ala-Korpela, M., & Smith, G. D. (2017) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2017.78 · Cited by 679
Self-citationCardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients
Ridker, P. M., Revkin, J., Amarenco, P., Brunell, R., Curto, M., Civeira, F., Flather, M., Glynn, R. J., Gregoire, J., Jukema, J. W., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1701488 · Cited by 624
Self-citationGenetic drug target validation using Mendelian randomisation
Schmidt, A. F., Finan, C., Gordillo‐Marañón, M., Asselbergs, F. W., Freitag, D. F., Patel, R. S., Tyl, B., Chopade, S., Faraway, R., Zwierzyna, M., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-16969-0 · Cited by 590
A Comparison of Two LDL Cholesterol Targets after Ischemic Stroke
Amarenco, P., Js, K., Labreuche, J., Charles, H., Abtan, J., Béjot, Y., Cabrejo, L., Jk, C., Ducrocq, G., Giroud, M., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1910355 · Cited by 581
2021 ESC Guidelines on cardiovascular disease prevention in clinical practice
Visseren, F. L. J., Mach, F., Smulders, Y. M., Carballo, D., Koskinas, K. C., Bäck, M., Bénétos, A., Biffi, A., Boavida, J.-M., Capodanno, D., et al. (2021) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwab154 · Cited by 586
Clinical review on triglycerides
Laufs, U., Parhofer, K. G., Ginsberg, H. N., & Hegele, R. A. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz785 · Cited by 544
Duan, Y., Gong, K., Xu, S., Zhang, F., Meng, X., & Han, J. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01125-5 · Cited by 538
Nordanstig, J., Behrendt, C., Baumgärtner, I., Belch, J. J. F., Bäck, M., Fitridge, R., Hinchliffe, R. J., Lejay, A., Mills, J. L., Rother, U., et al. (2023) · European Journal of Vascular and Endovascular Surgery · doi:10.1016/j.ejvs.2023.08.067 · Cited by 575
Impact of Lipids on Cardiovascular Health
Ference, B. A., Graham, I., Tokgozoglu, L., & Catapano, A. L. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.06.046 · Cited by 511
Lindahl, B., Baron, T., Erlinge, D., Hadziosmanovic, N., Nordenskjöld, A. E., Gard, A., & Jernberg, T. (2017) · Circulation · doi:10.1161/circulationaha.116.026336 · Cited by 490
The Magic of Randomization versus the Myth of Real-World Evidence
Collins, R., Bowman, L. J., Landray, M., & Peto, R. (2020) · New England Journal of Medicine · doi:10.1056/nejmsb1901642 · Cited by 490
Self-citationPrimary prevention of cardiovascular disease: A review of contemporary guidance and literature
Stewart, J., Manmathan, G. P. R., & Wilkinson, P. (2017) · JRSM Cardiovascular Disease · doi:10.1177/2048004016687211 · Cited by 516
Updated Cardiovascular Prevention Guideline of the Brazilian Society of Cardiology - 2019
Précoma, D. B., de Oliveira, G. M. M., Simão, A. F. L., Dutra, Ó. P., Coelho-Filho, O. R., Izar, M. C. D. O., Póvoa, R., Giuliano, I. D. C. B., Filho, A. C. D. A., Machado, C. A., et al. (2019) · Arquivos Brasileiros de Cardiologia · doi:10.5935/abc.20190204 · Cited by 507
Köhler‐Forsberg, O., N. Lydholm, C., Hjorthøj, C., Nordentoft, M., Mors, O., & Benros, M. E. (2019) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.13016 · Cited by 432
Safety and efficacy of statin therapy
Adhyaru, B. B., & Jacobson, T. A. (2018) · Nature Reviews Cardiology · doi:10.1038/s41569-018-0098-5 · Cited by 424
Long-term evolocumab in patients with established atherosclerotic cardiovascular disease
O’Donoghue, M. L., Giugliano, R. P., Wiviott, S. D., Atar, D., Keech, A., Kuder, J. F., Im, K., Murphy, S. A., Flores-Arredondo, J. H., López, J. A. G., et al. (2022) · Circulation · doi:10.1161/circulationaha.122.061620 · Cited by 410
Mach, F., Ray, K. K., Wiklund, O., Corsini, A., Catapano, A. L., Bruckert, E., De Backer, G., Hegele, R. A., Hovingh, G. K., Jacobson, T. A., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehy182 · Cited by 370
Primary and Secondary Prevention of Ischemic Stroke and Cerebral Hemorrhage
Diener, H., & Hankey, G. J. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.12.072 · Cited by 394
PCSK9 inhibitors: clinical evidence and implementation
Sabatine, M. S. (2019) · Nature Reviews Cardiology · doi:10.1038/s41569-018-0107-8 · Cited by 338
Mechanisms, Consequences, and Prevention of Coronary Graft Failure
Gaudino, M. F. L., Antoniades, C. A., Benedetto, U., Deb, S., Franco, A. D., Giammarco, G. D., Fremes, S. E., Glineur, D., Grau, J. B., He, G., et al. (2017) · Circulation · doi:10.1161/circulationaha.117.027597 · Cited by 366
Gupta, A., Thompson, D., Whitehouse, A., Collier, T., Dahlof, B., Poulter, N., Collins, R., & Sever, P. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31075-9 · Cited by 343
Self-citationCoronary Artery Disease in Patients ≥80 Years of Age
Madhavan, M. V., Gersh, B. J., Alexander, K. P., Granger, C. B., & Stone, G. W. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.12.068 · Cited by 333
on behalf of the China Kadoorie Biobank Collaborative Group, Sun, L., Clarke, R., Bennett, D., Yu, C., Walters, R. G., Hill, M., Parish, S., Millwood, I. Y., Bian, Z., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0366-x · Cited by 318
Self-citationGencer, B., Marston, N. A., Im, K., Cannon, C. P., Sever, P., Keech, A., Braunwald, E., Giugliano, R. P., & Sabatine, M. S. (2020) · The Lancet · doi:10.1016/s0140-6736(20)32332-1 · Cited by 318
Self-citationAutier, P., Mullie, P., Macacu, A., Dragomir, M., Boniol, M., Coppens, K., Pizot, C., & Boniol, M. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30357-1 · Cited by 322
Brunner, F. J., Waldeyer, C., Ojeda, F., Salomaa, V. V., Kee, F., Sans, S., Thorand, B., Giampaoli, S., Brambilla, P., Tunstall‐Pedoe, H., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)32519-x · Cited by 322
Richardson, T. G., Leyden, G. M., Wang, Q., Bell, J. A., Elsworth, B., Davey Smith, G., & Holmes, M. V. (2022) · PLOS Biology · doi:10.1371/journal.pbio.3001547 · Cited by 304
2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia
Blumenthal, R. S., Morris, P. B., Gaudino, M., Johnson, H. M., Anderson, T. S., Bittner, V. A., Blankstein, R., Brewer, L. C., Cho, L., de Ferranti, S. D., et al. (2026) · JACC · doi:10.1016/j.jacc.2025.11.016 · Cited by 304
Self-citationCardiomyopathy in obesity, insulin resistance and diabetes
Nakamura, M., & Sadoshima, J. (2019) · The Journal of Physiology · doi:10.1113/jp276747 · Cited by 294
Lipid management in patients with chronic kidney disease
Ferro, C. J., Mark, P. B., Kanbay, M., Sarafidis, P. A., Heine, G. H., Rossignol, P., Massy, Z. A., Mallamaci, F., Valdivielso, J. M., Małyszko, J., et al. (2018) · Nature Reviews Nephrology · doi:10.1038/s41581-018-0072-9 · Cited by 281
Reith, C. A., Baigent, C., Blackwell, L. S., Emberson, J., Spata, E., Davies, K., Halls, H. J., Holland, L., Wilson, K., Armitage, J., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(22)01545-8 · Cited by 301
Self-citationThe Evolving Future of PCSK9 Inhibitors
Rosenson, R. S., Hegele, R. A., Fazio, S., & Cannon, C. P. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.04.054 · Cited by 264
Systematic review: human gut dysbiosis induced by non-antibiotic prescription medications
Le Bastard, Q., Al‐Ghalith, G. A., Grégoire, M., Chapelet, G., Javaudin, F., Dailly, E., Batard, E., Knights, D., & Montassier, E. (2018) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.14451 · Cited by 263
Sabatine, M. S., De Ferrari, G. M., Giugliano, R. P., Huber, K., Lewis, B. S., Ferreira, J., Kuder, J. F., Murphy, S. A., Wiviott, S. D., Kurtz, C. E., et al. (2018) · Circulation · doi:10.1161/circulationaha.118.034309 · Cited by 255
Self-citationCai, T., Abel, L., Langford, O., Monaghan, G., Aronson, J. K., Stevens, R., Lay-Flurrie, S. L., Koshiaris, C., McManus, R. J., Hobbs, R. F., et al. (2021) · BMJ · doi:10.1136/bmj.n1537 · Cited by 237
Disorders of lipid metabolism. Clinical Guidelines 2023
Владиславович, Е. М., Kukharchuk, V. V., Сергиенко, И. В., Alieva, A. S., Antsiferov, M. B., Ansheles, A. A., Arabidze, G. G., Dm, A., Arutyunov, G. P., Ахмеджанов, Н. М., et al. (2023) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2023-5471 · Cited by 270
Walker, V. M., Smith, G. D., Davies, N. M., & Martin, R. M. (2017) · International Journal of Epidemiology · doi:10.1093/ije/dyx207 · Cited by 216
Self-citation2024 Clinical practice guidelines for Hypertension in adults
Кобалава, Ж. Д., Конради, А. О., Nedogoda, S. V., Shlyakhto, E. V., Arutyunov, G. P., Баранова, Е. И., Барбараш, О. Л., Bobkova, N. V., Boytsov, S. A., Bubnova, M. G., et al. (2024) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2024-6117 · Cited by 274
Reverse Causality in Cardiovascular Epidemiological Research: More Common Than Imagined?
Sattar, N., & Preiss, D. (2017) · Circulation · doi:10.1161/circulationaha.117.028307 · Cited by 211
Self-citationSabatine, M. S., Wiviott, S. D., Im, K., Murphy, S. A., & Giugliano, R. P. (2018) · JAMA Cardiology · doi:10.1001/jamacardio.2018.2258 · Cited by 214
PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease
Schmidt, A. F., Pearce, L. S., Wilkins, J. T., Overington, J. P., Hingorani, A. D., & Casas, J. P. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011748.pub2 · Cited by 203
Primary Prevention of Cardiovascular Disease in Diabetes Mellitus
Newman, J. D., Schwartzbard, A. Z., Weintraub, H. S., Goldberg, I. J., & Berger, J. S. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.07.001 · Cited by 205
Landmesser, U., Chapman, M. J., Stock, J. K., Amarenco, P., Belch, J. J. F., Borén, J., Farnier, M., Ference, B. A., Gielen, S., Graham, I., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehx549 · Cited by 200
Statin-induced myalgia and myositis: an update on pathogenesis and clinical recommendations
Selva-O’Callaghan, A., Alvarado-Cárdenas, M., Pinal‐Fernandez, I., Araguás, E. T., Milisenda, J. C., Martínez, M. Á., Marín, A., Labrador‐Horrillo, M., Juárez, C., & Grau‐Junyent, J. M. (2018) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2018.1440206 · Cited by 206
Turner, R. M., & Pirmohamed, M. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm9010022 · Cited by 206
Ruscica, M., Ferri, N., Banach, M., Sirtori, C. R., & Corsini, A. (2022) · Cardiovascular Research · doi:10.1093/cvr/cvac020 · Cited by 218
Unmet Need for Adjunctive Dyslipidemia Therapy in Hypertriglyceridemia Management
Ganda, O. P., Bhatt, D. L., Mason, R. P., Miller, M., & Boden, W. E. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.04.061 · Cited by 195
Sex- and Gender-Based Pharmacological Response to Drugs
Mauvais‐Jarvis, F., Berthold, H. K., Campesi, I., Carrero, J. J., Dhakal, S., Franconi, F., Gouni‐Berthold, I., Heiman, M. L., Kautzky‐Willer, A., Klein, S. L., et al. (2021) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000206 · Cited by 203
Optimizing cholesterol treatment in patients with muscle complaints
Rosenson, R. S., Baker, S., Banach, M., Borow, K. M., Braun, L. T., Bruckert, E., Brunham, L. R., Catapano, A. L., Elam, M. B., Mancini, G. B. J., et al. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.07.752 · Cited by 193
Statin treatment and muscle symptoms: series of randomised, placebo controlled n-of-1 trials
Herrett, E., Williamson, E., Brack, K., Beaumont, D., Perkins, A., Thayne, A., Shakur-Still, H., Roberts, I., Prowse, D., Goldacre, B., et al. (2021) · BMJ · doi:10.1136/bmj.n135 · Cited by 191
Self-citationTong, T. Y. N., Appleby, P. N., Bradbury, K. E., Perez‐Cornago, A., Travis, R. C., Clarke, R., & Key, T. J. (2019) · BMJ · doi:10.1136/bmj.l4897 · Cited by 201
Prevalence of dyslipidaemia among adults in Africa: a systematic review and meta-analysis
Noubiap, J. J., Bigna, J. J., Nansseu, J. R., Nyaga, U. F., Balti, E. V., Echouffo-Tcheugui, J. B., & Kengne, A. P. (2018) · The Lancet Global Health · doi:10.1016/s2214-109x(18)30275-4 · Cited by 188
Holmes, M. V., Richardson, T. G., Ference, B. A., Davies, N. M., & Davey Smith, G. (2021) · Nature Reviews Cardiology · doi:10.1038/s41569-020-00493-1 · Cited by 184
Self-citationPinal‐Fernandez, I., Casal-Domínguez, M., & Mammen, A. L. (2017) · Medicina Clínica · doi:10.1016/j.medcli.2017.11.030 · Cited by 192
The LDL cumulative exposure hypothesis: evidence and practical applications
Ference, B. A., Braunwald, E., & Catapano, A. L. (2024) · Nature Reviews Cardiology · doi:10.1038/s41569-024-01039-5 · Cited by 196
Mendelian randomisation in cardiovascular research: an introduction for clinicians
Bennett, D., & Holmes, M. V. (2017) · Heart · doi:10.1136/heartjnl-2016-310605 · Cited by 181
Yebyo, H. G., Aschmann, H. E., Kaufmann, M., & Puhan, M. A. (2019) · American Heart Journal · doi:10.1016/j.ahj.2018.12.007 · Cited by 181
Effect of Statin Treatment vs Usual Care on Primary Cardiovascular Prevention Among Older Adults
Han, B. H., Sutin, D. G., Williamson, J. D., Davis, B. R., Piller, L. B., Pervin, H., Pressel, S., & Blaum, C. S. (2017) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2017.1442 · Cited by 178
Nussbaumerová, B., & Rosolová, H. (2023) · Current Atherosclerosis Reports · doi:10.1007/s11883-023-01167-2 · Cited by 197
Guaraldi, G., Malagoli, A., Calcagno, A., Mussi, C., Celesia, B. M., Carli, F., Piconi, S., Socio, G. V. D., Cattelan, A. M., Orofino, G., et al. (2018) · BMC Geriatrics · doi:10.1186/s12877-018-0789-0 · Cited by 179
Newman, C. B., Blaha, M. J., Boord, J. B., Cariou, B., Chait, A., Fein, H. G., Ginsberg, H. N., Goldberg, I. J., Murad, M. H., Subramanian, S., et al. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa674 · Cited by 182
Lerman, J. B., Joshi, A. A., Chaturvedi, A., Aberra, T. M., Dey, A. K., Rodante, J. A., Salahuddin, T., Chung, J. H. N., Rana, A., Teague, H., et al. (2017) · Circulation · doi:10.1161/circulationaha.116.026859 · Cited by 186
Statin use and risk of new-onset diabetes: A meta-analysis of observational studies
Casula, M., Mozzanica, F., Scotti, L., Tragni, E., Pirillo, A., Corrao, G., & Catapano, A. L. (2017) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2017.03.001 · Cited by 179
Sex Differences in High-Intensity Statin Use Following Myocardial Infarction in the United States
Peters, S. A. E., Colantonio, L. D., Zhao, H., Bittner, V., Dai, Y., Farkouh, M. E., Monda, K. L., Safford, M. M., Muntner, P., & Woodward, M. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.02.032 · Cited by 173
The dawn of a new era of targeted lipid-lowering therapies
Tokgözoğlu, L., & Libby, P. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehab841 · Cited by 171
Inflammation as a Therapeutic Target in Atherosclerosis
Nguyen, M. T., Fernando, S., Schwarz, N., Tan, J. T. M., Bursill, C. A., & Psaltis, P. J. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8081109 · Cited by 176
Unveiling the Role of Inflammation and Oxidative Stress on Age-Related Cardiovascular Diseases
de Almeida, A. J. P. O., Rezende, M. S. D. A., Dantas, S. H., Silva, S. D. L., de Oliveira, J. C. P. L., de Azevedo, F. D. L. A. A., Alves, R. M. F. R., de Menezes, G. M. S., dos Santos, P. F., Gonçalves, T. A. F., et al. (2020) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2020/1954398 · Cited by 173
Pennells, L. A. M., Kaptoge, S. K., Wood, A., Sweeting, M., Zhao, X., White, I. R., Burgess, S., Willeit, P., Bolton, T. R., Moons, K. G. M., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehy653 · Cited by 164
Self-citationIntegrated Polygenic Tool Substantially Enhances Coronary Artery Disease Prediction
Riveros-Mckay, F., Weale, M. E., Moore, R., Selzam, S., Krapohl, E. M. L., Sivley, R. M., Tarran, W. A., Sørensen, P. B., Lachapelle, A. S., Griffiths, J. A., et al. (2021) · Circulation Genomic and Precision Medicine · doi:10.1161/circgen.120.003304 · Cited by 163
Targeting inflammation to reduce cardiovascular disease risk: A realistic clinical prospect?
Welsh, P., Grassia, G., Botha, S., Sattar, N., & Maffia, P. (2017) · British Journal of Pharmacology · doi:10.1111/bph.13818 · Cited by 164
Prabhakaran, D., Anand, S., Watkins, D., Gaziano, T., Wu, Y., Mbanya, J. C., Nugent, R., Ajay, V. S., Afshin, A., Adler, A., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(17)32471-6 · Cited by 162
Self-citationFerence, B. A., Cannon, C. P., Landmesser, U., Lüscher, T. F., Catapano, A. L., & Ray, K. K. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehx450 · Cited by 161
Metadata
- Authors
- Collins, R., Reith, C., Emberson, J., Armitage, J., Baigent, C., Blackwell, L., Blumenthal, R., Danesh, J., Smith, G. D., DeMets, D., Evans, S., Law, M., MacMahon, S., Martin, S., Neal, B., Poulter, N., Preiss, D., Ridker, P., Roberts, I., Rodgers, A., Sandercock, P., Schulz, K., Sever, P., Simes, J., Smeeth, L., Wald, N., Yusuf, S., & Peto, R.
- Affiliations
- University of Oxford (GB)
- Johns Hopkins University (US)
- University of Cambridge (GB)
- University of Bristol (GB)
- University of Wisconsin–Madison (US)
- University of London (GB)
- The University of Sydney (AU)
- Imperial College London (GB)
- Brigham and Women's Hospital (US)
- University of Edinburgh (GB)
- University of North Carolina at Chapel Hill (US)
- Population Health Research Institute (CA)
- Corresponding author
- Collins, Rory
- ORCID
- Collins, Rory
- Reith, Christina
- Emberson, Jonathan
- Armitage, Jane
- Baigent, Colin
- Blumenthal, Roger
- Danesh, John
- Smith, George Davey
- DeMets, David
- Evans, Stephen
- MacMahon, Stephen
- Martin, Seth
- Neal, Bruce
- Poulter, Neil
- Preiss, David
- Ridker, Paul
- Roberts, Ian
- Rodgers, Anthony
- Sandercock, Peter
- Schulz, Kenneth
- Smeeth, Liam
- Wald, Nicholas
- Yusuf, Salim
- Peto, Richard
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2016-11
- Volume
- 388
- Issue
- 10059
- Pages
- 2532-2561
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W2519634482
- Cited by
- 1,857
- References
- 299
- Citations by year
- 2026: 136 · 2025: 136 · 2024: 150 · 2023: 166 · 2022: 187 · 2021: 229 · 2020: 192 · 2019: 218 · 2018: 206 · 2017: 202 · 2016: 31
- FWCI
- 43.45
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- The Lancet (publishedVersion)
- PubMed (publishedVersion)
- Explore Bristol Research (publishedVersion, other-oa)
- LSHTM Research Online (London School of Hygiene and Tropical Medicine) (acceptedVersion)
- Edinburgh Research Explorer (University of Edinburgh) (submittedVersion, cc-by-nc-nd)
- Queen Mary Research Online (Queen Mary University of London) (submittedVersion)
- Bristol Research (University of Bristol) (submittedVersion, other-oa)
- Spiral (Imperial College London) (submittedVersion, cc-by-nc-nd)
- Funders
- Cancer Research UK (16896)
- National Institute for Health and Care Research (NF-SI-0611-10057, HTA/14/49/159, 14/49/159, NF-SI-0513-10059)
- British Heart Foundation (SP/08/010/25939, SP/14/3/31114, RG/13/13/30194)
- Medical Research Council (MR/K006584/1, MR/L003120/1)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Antiplatelet Therapy and Cardiovascular Diseases
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
- Keywords
- statin therapy, LDL cholesterol lowering, cardiovascular disease prevention, secondary prevention, primary prevention, absolute risk reduction, statin adverse effects, myopathy, rhabdomyolysis, new-onset diabetes, hemorrhagic stroke, atorvastatin, long-term treatment, evidence evaluation, cardiovascular risk assessment, cost-effectiveness, randomized controlled trials, meta-analysis
- MeSH terms
- Anticholesteremic Agents, Clinical Trials as Topic, Coronary Disease, Humans, Cholesterol, LDL, Myocardial Infarction, Safety, Risk Assessment, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Simvastatin, Stroke, Drug-Related Side Effects and Adverse Reactions
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
